Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

@article{Dahlf2005PreventionOC,
  title={Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri},
  author={Bj{\"o}rn Dahl{\"o}f and Peter S Sever and Neil R. Poulter and Hans Wedel and D Gareth Beevers and Mark J. Caulfield and Rory Collins and Sverre E. Kjeldsen and Arni Kristinsson and Gordon T. Mcinnes and Jesper Mehlsen and Markku S Nieminen and Eoin O’Brien and Jan {\"O}stergren},
  journal={The Lancet},
  year={2005},
  volume={366},
  pages={895-906}
}
BACKGROUND The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics and beta blockers used. For a given reduction in blood pressure, some suggested that newer agents would confer advantages over diuretics and beta blockers. Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril… Expand
Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension
Dahlof B, Sever PS, Poulter NR, et al . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide asExpand
Which patients would benefit the most from the perindopril-amlodipine combination?
TLDR
The combination of amlodipine and perindopril should prove particularly beneficial in patients with coronary artery disease and either hypertension or anginal symptoms, as well as elderly populations or patients with chronic kidney disease. Expand
Blood pressure lowering therapy in older and younger hypertensive patients.
TLDR
The primary endpoint was not significantly different between the two treatment regimens at that time, at least partly explained by the premature termination of the trial, and the incidence of most of the seven secondary endpoints was significantly lower on the amlodipine-based regimen than on the atenolol- based regimen. Expand
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes
TLDR
In the large diabetic subgroup in the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial, the benefits of amlodipine-based treatment, compared with atenolol- based treatment, on the incidence of total cardiovascular events and procedures was significant and similar to that observed in the total trial population. Expand
Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes.
TLDR
The OLM-AML combination is safe, well tolerated, and not inferior to the combination of PER/AML in lowering CBP and CBP-derived parameters in diabetic patients and provides longer-lasting efficacy in terms of CBP reduction compared to PER/ AML. Expand
The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension
TLDR
The combination of OLM/AMl was superior to PER/AML in reducing CSBP and other efficacy measures, including a significantly higher rate of BP normalization. Expand
A new dimension in hypertension management with the amlodipine/perindopril combination
TLDR
Analysis of long-term BP variability provided a further explanation for the reduction of cardiovascular events with amlodipine/perindopril in ASCOT, and the combination of perindoprine and amlODipine seems an ideal logical evidence-based pair of antihypertensive agents to select. Expand
Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
TLDR
Amlodipine plus candesartan demonstrated a more favorable effect on reducing cardiovascular events in patients with hypertension with CAD compared to amlodIPine-based therapy without candesartsartan. Expand
Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
TLDR
These trials demonstrate that while perindopril, in addition to standard recommended therapy, has a potential role in preventing cardiovascular events in hypertensive patients, its role in the management of patients with stable CAD is clearly established. Expand
Combination of Amlodipine plus Angiotensin Receptor Blocker or Diuretics in High-Risk Hypertensive Patients
TLDR
Long-term combination therapy with amlodipine plus telmisartan or amloderide plus amiloride/hydrochlorothiazide was not only well tolerated but also efficacious in reducing BP levels with acceptable control rates in the majority of hypertensive patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
TLDR
Nifedipine once daily and co-amilozide were equally effective in preventing overall cardiovascular or cerebrovascular complications in high-risk patients with hypertension. Expand
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
TLDR
Diltiazem was as effective as treatment based on diuretics, beta-blockers, or both in preventing the combined primary endpoint of all stroke, myocardial infarction, and other cardiovascular death. Expand
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan. Expand
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
TLDR
The CONVINCE trial did not demonstrate equivalence of a COER verapamil-based antihypertensive regimen compared with a regimen beginning with a diuretic or beta-blocker, and data indicate that the effectiveness of calcium-channel therapy in reducing cardiovascular disease is similar but not better than diuresis treatment. Expand
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial
TLDR
The study has 80% power (at the 5% level) to detect a relative difference of 20% in CHD endpoints between the calcium channel blocker-based regimen and the β-blocker-based program and the lipid-lowering limb of the study has 90% power at the 1% level. Expand
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
TLDR
There were no significant differences in total major cardiovascular events between regimens based on ACE inhibitors, calcium antagonists, or diuretics or beta blockers, although ACE-inhibitor-based regimens reduced blood pressure less. Expand
Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial
TLDR
The greater efficacy of lacidipine on carotid IMT progression and number of plaques per patient, despite a smaller ambulatory blood pressure reduction, indicates an antiatherosclerotic action of lacIDipine independent of its antihypertensive action. Expand
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
TLDR
Serial mean matching for differences in systolic blood-pressure attenuated HRs for coronary and stroke events to a similar extent as did adjustments for systols in Cox-regression analyses, which noted no temporal link between size of differences in blood pressure and different event rates. Expand
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
TLDR
Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed. Expand
Old antihypertensives and new diabetes
TLDR
When compared with placebo, ACE inhibition by ramipril or by the ARB, candesartan, both decrease the incidence of new diabetes, raising the hypothesis that these agents actually prevent the changes leading to insulin resistance, possibly by lessening the adverse effects of angiotensin II on the endothelium. Expand
...
1
2
3
4
...